Radezolid

DB12339InvestigationalSmall molecule

Radezolid has been used in trials studying the treatment of Abscess, Bacterial Skin Diseases, Streptococcal Infections, Infectious Skin Diseases, and Staphylococcal Skin Infections, among others.

Formula / weight: C₂₂H₂₃FN₆O₃ · 438.463 g/mol (avg)
Code names: AND RX-01_667 · RX-013 · RX-103 · RX-1741

Resolves to

Compound

UNII53PC6LO35WCAS869884-78-6ChEMBLCHEMBL455461PubChem11224409

Structure

InChIKeyBTTNOGHPGJANSW-IBGZPJMESA-NSMILESCC(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C(F)=C1)C1=CC=C(CNCC2=CN=NN2)C=C1

Targets

Q9P2E9RRBP1Q2G0P0rplA

What you can answer from here — as of September 21, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

56Drug interactionsStructured to mechanism, not free text

2Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Radezolid, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account